Intellia Therapeutics to Hold Conference Call to Discuss Fourth Quarter and Full-Year 2023 Earnings and Company Updates
Intellia Therapeutics, Inc. (NASDAQ:NTLA) to announce Q4 and full-year 2023 financial results and operational highlights on February 22, 2024. The conference call will focus on their CRISPR-based therapies.
02/14/2024 - 07:30 AM
CAMBRIDGE, Mass., Feb. 14, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, will present its fourth quarter and full-year 2023 financial results and operational highlights in a conference call on February 22, 2024, at 8 a.m. ET.
To join the call:
U.S. callers should dial 1-833-316-0545 and international callers should dial 1-412-317-5726, approximately five minutes before the call. All participants should ask to be connected to the Intellia Therapeutics conference call. Please visit this link for a simultaneous live webcast of the call. A replay of the call will be available through the Events and Presentations page of the Investors & Media section on Intellia’s website at www.intelliatx.com , beginning on February 22, 2024, at 12 p.m. ET.
About Intellia Therapeutics
Intellia Therapeutics, Inc. (NASDAQ:NTLA) is a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies. The company’s in vivo programs use CRISPR to enable precise editing of disease-causing genes directly inside the human body. Intellia’s ex vivo programs use CRISPR to engineer human cells outside the body for the treatment of cancer and autoimmune diseases. Intellia’s deep scientific, technical and clinical development experience, along with its people, is helping set the standard for a new class of medicine. To harness the full potential of gene editing, Intellia continues to expand the capabilities of its CRISPR-based platform with novel editing and delivery technologies. Learn more at intelliatx.com and follow us @intelliatx .
Intellia Contacts:
Investors: ian.karp@intelliatx.com
Lina Lilina.li@intelliatx.com
When will Intellia Therapeutics announce its Q4 and full-year 2023 financial results?
Intellia Therapeutics will announce its Q4 and full-year 2023 financial results on February 22, 2024.
What time is the conference call scheduled for?
The conference call is scheduled for 8 a.m. ET on February 22, 2024.
How can U.S. callers join the conference call?
U.S. callers can dial 1-833-316-0545 to join the conference call.
Where can participants find a live webcast of the call?
Participants can find a live webcast of the call at the provided link.
When will the replay of the call be available?
The replay of the call will be available on February 22, 2024, at 12 p.m. ET.
Intellia Therapeutics Inc
NTLA Rankings
#4821 Ranked by Stock Gains
NTLA Stock Data
Industry
Pharmaceutical Preparation Manufacturing
Sector
Manufacturing
Tags
Health Technology, Biotechnology, Manufacturing, Pharmaceutical Preparation Manufacturing
Country
US
City
Cambridge
About NTLA
intellia therapeutic’s core mission is to develop curative medicines, utilizing the promise of the crispr/cas9 gene editing technology. the development of crispr/cas9 gene editing technology opens a new frontier in biomedical research and clinical intervention. adapted from a natural cellular process, crispr/cas9 permits the editing of any gene in any organism with unprecedented simplicity and flexibility. the incredible potential of this technology for treating human genetic disease inspired a group of life science veterans to create intellia therapeutics. intellia was founded in 2014 by caribou biosciences and atlas venture, along with a consortium of scientists who have helped define the space. intellia therapeutics holds exclusive access to a broad intellectual property portfolio covering the application of crispr/cas9 technology for human therapeutic use. intellia has built an experienced team of individuals to meet the challenges of bringing crispr/cas9 therapeutics to the
